Health Care [ 3/12 ] | Biotechnology [ 18/74 ]
NASDAQ | Common Stock
MacroGenics, Inc., a clinical-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes antibody-based therapeutics for the treatment of cancer in the United States.
The company's product pipeline includes lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4 for the treatment of mCRPC and docetaxel that is in phase 2 clinical trials, as well as for the treatment of platinum-resistant ovarian cancer and clear cell gynecologic cancer which has completed phase 1 clinical trial; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload; MGC028, an antibody-drug conjugates (ADC) that targets ADAM9 and delivers a novel TOP1i-based linker-payload for the treatment of solid tumors, which is in phase 1 clinical trials; MGC030, a ADC molecule that targets an undisclosed antigen expressed across several solid tumors, which is in preclinical trials.
It is also developing T-cell engager programs.
The company has collaborations with TerSera Therapeutics LLC; Incyte Corporation; and Gilead Sciences, Inc. MacroGenics, Inc. was incorporated in 2000 and is headquartered in Rockville, Maryland.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| May 13, 26 | -0.58 Increased by +10.77% | -0.55 Decreased by -5.45% |
| Feb 19, 26 | -0.22 Increased by +73.11% | -0.27 Increased by +18.40% |
| Nov 12, 25 | 0.27 Decreased by -70.00% | -0.50 Increased by +154.00% |
| Aug 14, 25 | -0.57 Increased by +35.96% | -0.47 Decreased by -21.28% |
| May 13, 25 | -0.65 Increased by +22.62% | -0.69 Increased by +5.80% |
| Mar 5, 25 | -0.82 Decreased by -9.07% | -0.59 Decreased by -38.64% |
| Nov 5, 24 | 0.90 Increased by +273.08% | 0.60 Increased by +50.00% |
| Aug 6, 24 | -0.89 Decreased by -27.14% | -0.59 Decreased by -50.85% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Mar 31, 26 | 20.77 M Increased by +57.48% | -36.77 M Increased by +10.39% | Decreased by -177.01% Increased by +43.10% |
| Dec 31, 25 | 41.23 M Increased by +132.53% | -14.15 M Increased by +8.21% | Decreased by -34.33% Increased by +60.52% |
| Sep 30, 25 | 72.84 M Decreased by -34.21% | 16.82 M Decreased by -70.13% | Increased by +23.09% Decreased by -54.59% |
| Jun 30, 25 | 22.24 M Increased by +105.99% | -36.25 M Increased by +34.88% | Decreased by -162.99% Increased by +68.38% |
| Mar 31, 25 | 13.19 M Increased by +44.90% | -41.04 M Increased by +21.37% | Decreased by -311.07% Increased by +45.74% |
| Dec 31, 24 | 17.73 M Increased by +65.39% | -15.42 M Increased by +66.53% | Decreased by -86.98% Increased by +79.76% |
| Sep 30, 24 | 110.71 M Increased by +964.81% | 56.31 M Increased by +220.78% | Increased by +50.86% Decreased by -69.87% |
| Jun 30, 24 | 10.80 M Decreased by -17.81% | -55.66 M Decreased by -196.86% | Decreased by -515.55% Decreased by -217.84% |